Summary of the Fragile X Messenger Ribonucleoprotein (FMRP) Series at the 18th NFXF International Conference
Dr. Talia Thompson summarizes the Fragile X Messenger Ribonucleoprotein (FMRP) series from the 18th NFXF International Conference
Summary of the Diagnosis and Treatment of Fragile X-Associated Tremor Ataxia Syndrome Panel Session
Dr. Michelle Tosin, a 2022 NFXF Junior Investigator, summarizes the Diagnosis and Treatment of Fragile X-associated Tremor Ataxia Syndrome session at the 18th International Fragile X Conference.
Summary of the Research Landscape Panel at the 18th International Fragile X Conference
Dr. Kate Shelly, a 2022 Jr. Investigator, summarizes the Research Landscape panel at the NFXF's 18th International Fragile X Conference.
Summary of the Fragile X Premutation Basic Science Research Session at the NFXF 18th International Fragile X Conference
Dr. Carolyn Yrigollen summarizes the Fragile X Premutation Basic Science Research session at the NFXF's 18th International Fragile X Conference.
Tetra Therapeutics: An Interview with Dr. Liz Berry-Kravis
Learn more about the ongoing Tetra trials in this 2-minute video with Dr. Liz Berry-Kravis
Antisense Oligonucleotide (ASO) therapy being explored in Fragile X syndrome!
A publication was released this week summarizing one lab’s discovery that could lead to a future treatment for Fragile X- ASO therapy.
The NFXF Heartland Chapter Hosts 8th Annual “Bike To X Out Fragile X”
The 8th Annual Bike to X Out Fragile X took place on a beautiful Saturday, June 3, 2023.
Allos Pharma Inc. Receives FDA Guidance and Support for their Phase 3 Trial of Arbaclofen in Fragile X Syndrome
Allos Pharma Inc. received invaluable FDA feedback on the design of their Phase 3 trial for arbaclofen for the treatment of Fragile X syndrome.
The effect of college degree attainment on neurodegenerative symptoms in genetically at-risk women
Researchers at the University of Wisconsin explored the relationship between obtaining a college degree and the manifestation of the neurodegenerative symptoms of FXTAS among women at elevated genetic risk.
Fragile X-associated tremor/ataxia syndrome rating scale: Revision and content validity using a mixed method approach
Researchers across several institutions set out to develop a revised version of the FXTAS-RS designed to specifically assess FXTAS motor signs.
The Fragile X Clinic and Research Program at Rush University Medical Center
Highlighting the Fragile X Clinic at Rush University Medical Center, a member of the National Fragile X Foundation’s Fragile X Clinical & Research Consortium (FXCRC)
Rare Across America 2023
Register now to join other rare disease advocates for meetings between August 7th - 18th. Sign up today for Rare Across America!
FMR1 CGG Repeats and Stress Influence Self-Reported Cognitive Functioning in Mothers
Researchers at the University of Wisconsin looked at the relationship and influence of FMR1 CGG repeats and stress on self-reported cognitive functioning in mothers.
The diagnostic experience of women with fragile X–associated primary ovarian insufficiency (FXPOI)
Researchers at Emory University conducted qualitative interviews with 24 women with FXPOI exploring how FMR1 screening, physician education, and supportive care impacted their experience receiving a diagnosis. Their results are in!
The Behavioral Neurogenetics Clinic at Stanford Medicine Children’s Health
Highlighting the Fragile X Clinic at Stanford University School of Medicine in California, a member of the National Fragile X Foundation’s Fragile X Clinical & Research Consortium (FXCRC)